On the Market | Published:

Epidermal immunization by a needle-free powder delivery technology: Immunogenicity of influenza vaccine and protection in mice

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Fenner, F. A successful eradication campaign. Global eradication of smallpox. Rev. Infect. Dis. 4, 916–930 (1997).

  2. 2

    Breman, J.G. & Arita, I. The confirmation and maintenance of small eradication. N. Engl. J. Med. 303, 1263–1273 (1980).

  3. 3

    Fynan, E.F et al. DNA vaccines: Protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc. Natl. Acad. Sci. USA 90, 11478–11482 (1993).

  4. 4

    Swain, W.F. et al. Tolerability and immune responses in humans to a PowderJect DNA vaccine for hepatitis B. Developmental Biology: Development and Clinical Progress of DNA Vaccines (ed. Brown, F., Cichutek, K. Robertson, J.) Vol. 104, 115–119 (Karger, Basel, Switzerland, 2000).

  5. 5

    Bos, J.D., Das, P.K. & Kapsenberg, M.L. in Skin Immune System (SIS) 2nd ed. (ed. Bos, J.D.) 9–15 (CRC, Boca Raton, Florida, 1997).

  6. 6

    Paul, A, Cevc, G. & Bachhawat, B.K. Transdernal immunization with an integral membrane component, gap junction protein, by means of ultradeformable drug carriers, transfersomes. Vaccine 16, 188–195 (1998).

  7. 7

    Teunissen M.B.M., Kapsenberg, M.L. & Bos, J.D. in Skin Immune System (SIS) 2nd ed. (ed. Bos, J.D.) 59–75 (CRC, Boca Raton, Florida, 1997).

  8. 8

    Glenn, G.M., Rao, M., Matyas, G.R. & Alving, C.R. Skin immunization made possible by cholera toxin. Nature 391, 851 (1998).

  9. 9

    Glenn, G.M. et al. Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. J. Immunol. 161, 3211–3214 (1998).

  10. 10

    Glenn, G.M., Scharton-Kersten, T., Vassell, R., Matyas, G.R. & Alving, C.R. Transcutaneous immunization with bacterial ADP-ribosylating exotoxin as antigens and adjuvants. Infect. Immun. 67, 1100–1106 (1999).

  11. 11

    Sarphie, D.F., Varadi, A., Bellhouse, B.J. & Ashcroft, S.J.H. Transdermal delivery of powdered bovine insulin to diabetic and bob-diabetic Wistar rats. Diabetes 44, 129 (1995).

  12. 12

    Sarphie, D.F., Johnson, B., Cormier, M., Burkoth, T.L. & Bellhouse, B.J. Bioavailability following transdermal powdered delivery (TPD) of radiolabeled insulin to hairless guinea pigs. J. Controlled Release 47, 61–69 (1997).

  13. 13

    Chen, D. et al. Evaluation of purified UspA from M. catarrhalis as a vaccine in a murine model after active immunization. Infect. Immun. 64, 1900–1905 (1996).

  14. 14

    Novak, M., Moldoveanu, Z., Schafer, D.P., Mestechy, J. & Compans, R.W. Murine model for evaluation of protective immunity to influenza virus. Vaccine 11, 55–60 (1993).

  15. 15

    Rimmelzwaan, G.F. et al. Influenza subtype cross-reactivities of haemagglutionation inhibiting and virus neutralizing serum antibodies induced by infection or vaccination with an ISCOM-based vaccine. Vaccine 17, 2512–2516 (1999).

  16. 16

    Saelens, X. et al. Protection of mice against a lethal influenza virus challenge after immunization with yeast-derived secreted influenza virus hemagglutinin. Eur. J. Biochem. 260, 166–175 (1999).

  17. 17

    Ulmer, J.B. et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259, 1745–1749 (1993).

  18. 18

    Webster, R.G. & Askonas, B.A. Cross-protection and cross-reactive cytotoxic T cells induced by influenza virus vaccines in mice. Eur. J. Immunol. 10, 396–401 (1980).

  19. 19

    Wraith, D.C., Vessey, A.E. & Askonas, B.A. Purified influenza virus nucleoprotein protects mice from lethal infection. J. Gen. Virol. 68, 433–440 (1987).

  20. 20

    Flohe, S.B., Bauer, C. & Moll, H. Antigen-pulsed epidermal Langerhans cells protect susceptible mice from infection with the intracellular parasite Leishmania major. Eur. J. Immunol. 28, 3800–3811 (1998).

  21. 21

    Condon, C. et al. DNA-based immunization by in vivo transfection of dendritic cells. Nature Med. 2, 1122–1128 (1996).

  22. 22

    Becker, Y. et al. HIV-peplotion vaccine. A novel approach to vaccination against AIDS by transepithelial transport of viral peptides to Langerhans cells for induction of cytotoxic T cells by HLA class I and CD1 molecules for long term protection. Adv. Exp. Med. Biol. 397, 97–104 (1996).

  23. 23

    Fadda, G. et al. Efficacy of hepatitis B immunization with reduced intradermal doses. Eur. J. Immunol. 3, 176–180 (1987).

  24. 24

    Bernard, K.W. et al. Preexposure immunization with intradermal human diploid cell rabies vaccine. Risk and benefits of primary and booster vaccination. J. Am. Med. Assoc. 257, 1059–1063 (1987).

  25. 25

    Horowitz, M.M., Ershler, W.B., McKinney, W.P. & Battiola, R.J. Duration of immunity after hepatitis B vaccination: Efficacy of low-dose booster vaccine. Ann. Intern. Med. 108, 185–189 (1988).

  26. 26

    Sheerar, M.G., Easterday, B.C. & Hinshaw, V.S. Antigenic conservation of H1N1 swine influenza viruses. J. Gen. Virol. 70, 3297–3303 (1989).

Download references

Acknowledgements

The authors thank J. Haynes, L. Roberts, S. Umlauf and W. Swain for evaluating the manuscript.

Author information

Correspondence to Dexiang Chen.

Rights and permissions

Reprints and Permissions

About this article

Further reading